MNK

Mallinckrodt NYSEAM:MNK Stock Report

Last Price

US$11.10

Market Cap

US$146.2m

7D

-0.09%

1Y

n/a

Updated

28 Nov, 2022

Data

Company Financials
MNK fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

MNK Stock Overview

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally.

Mallinckrodt plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mallinckrodt
Historical stock prices
Current Share PriceUS$11.10
52 Week HighUS$31.00
52 Week LowUS$0.10
Beta0
1 Month Change-28.34%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-40.00%

Recent News & Updates

Recent updates

Shareholder Returns

MNKUS PharmaceuticalsUS Market
7D-0.09%1.5%0.3%
1Yn/a12.2%-20.5%

Return vs Industry: Insufficient data to determine how MNK performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how MNK performed against the US Market.

Price Volatility

Is MNK's price volatile compared to industry and market?
MNK volatility
MNK Average Weekly Movement15.0%
Pharmaceuticals Industry Average Movement10.8%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: MNK is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: Insufficient data to determine MNK's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
18672,789Siggi Olafssonhttps://www.mallinckrodt.com

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products.

Mallinckrodt plc Fundamentals Summary

How do Mallinckrodt's earnings and revenue compare to its market cap?
MNK fundamental statistics
Market CapUS$146.20m
Earnings (TTM)-US$867.10m
Revenue (TTM)US$2.02b

0.1x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MNK income statement (TTM)
RevenueUS$2.02b
Cost of RevenueUS$1.34b
Gross ProfitUS$682.60m
Other ExpensesUS$1.55b
Earnings-US$867.10m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-65.83
Gross Margin33.76%
Net Profit Margin-42.88%
Debt/Equity Ratio166.5%

How did MNK perform over the long term?

See historical performance and comparison